SAN DIEGO, March 14, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com), San Diego Hospice (the "Hospice") and The Institute for Palliative Medicine today announced the signing of a clinical development collaboration to study the use of the Company's NexACT® Technology in the hospice setting. Clinicians at the Hospice will be evaluating the topical delivery of common hospice medications to determine if the use of such products with the Company's NexACT® drug delivery technology can have greater efficacy in delivering certain drugs to Hospice patients.
